Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Furiex receives FDA fast track designation for IBS drug
The FDA’s fast track programme is designed to facilitate the development and accelerate the review of new drugs intended to treat serious or life-threatening diseases and that show
The FDA’s fast track programme is designed to facilitate the development and accelerate the review of new drugs intended to treat serious or life-threatening diseases and that show
The randomized, single-blind, non-inferiority trial will compare the Synergy Stent to the Promus Element Everolimus-Eluting Coronary Stent in patients with a single de novo native coronary artery lesion.
Matrix claims that Pantoprazole Sodium DR tablets, a proton pump inhibitor drug, are generic version of Wyeth‘s Protonix DR tablets. Protonix is in a group of drugs called
CompleteSpend is a compliance reporting system that collects, aggregates, standardizes and reports spend data based on current state and pending federal regulations. HMS and Alanda combinedly offer an
The formulations facility will produce 3 billion tablets and capsules per annum, which will boost the company’s formulation capacity to nearly10 billion tablets. Torrent’s domestic formulations business grew
The transaction will enhance Novartis’s tools and services that aim to improve health outcomes for patients by advancing the ability to define and monitor individualized treatment programs. Under
Senesco was previously granted orphan drug status for SNS01-T. Senesco plans to evaluate SNS01-T in patients with relapsed or refractory disease who have failed at least two standard
The BRF113683 Phase III study compares GSK’436, a BRAF inhibitor, to dacarbazine (DTIC) in previously untreated patients with BRAF V600 mutated advanced or metastatic melanoma. The METRIC study
The trial has already recruited 240-patients. The only aspect of the trial that stopped for a period of time was the enrollment of additional new patients beyond the
The pivotal Phase 3 clinical trial is designed as an outpatient study of the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of DR Cysteamine dosed every 12 hours